These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21970688)

  • 1. Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    Kuwahara A; Yamamori M; Kadoyama K; Nishiguchi K; Nakamura T; Miki I; Tamura T; Okuno T; Omatsu H; Sakaeda T
    J Exp Clin Cancer Res; 2011 Oct; 30(1):94. PubMed ID: 21970688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    Tamura T; Kuwahara A; Yamamori M; Nishiguchi K; Nakamura T; Okuno T; Miki I; Manabe Y; Sakaeda T
    Int J Med Sci; 2012; 9(10):833-7. PubMed ID: 23155356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    Kuwahara A; Yamamori M; Fujita M; Okuno T; Tamura T; Kadoyama K; Okamura N; Nakamura T; Sakaeda T
    J Exp Clin Cancer Res; 2010 Jul; 29(1):100. PubMed ID: 20646319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    Kuwahara A; Yamamori M; Nishiguchi K; Okuno T; Chayahara N; Miki I; Tamura T; Inokuma T; Takemoto Y; Nakamura T; Kataoka K; Sakaeda T
    Int J Med Sci; 2009 Sep; 6(6):305-11. PubMed ID: 19834547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.
    Okuno T; Tamura T; Yamamori M; Chayahara N; Yamada T; Miki I; Okamura N; Kadowaki Y; Shirasaka D; Aoyama N; Nakamura T; Okumura K; Azuma T; Kasuga M; Sakaeda T
    Am J Clin Oncol; 2007 Jun; 30(3):252-7. PubMed ID: 17551301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.
    Kuwahara A; Yamamori M; Nishiguchi K; Okuno T; Chayahara N; Miki I; Tamura T; Kadoyama K; Inokuma T; Takemoto Y; Nakamura T; Kataoka K; Sakaeda T
    Int J Med Sci; 2010 Jan; 7(1):48-54. PubMed ID: 20151048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    Omatsu H; Kuwahara A; Yamamori M; Fujita M; Okuno T; Miki I; Tamura T; Nishiguchi K; Okamura N; Nakamura T; Azuma T; Hirano T; Ozawa K; Hirai M
    Int J Med Sci; 2013; 10(12):1755-60. PubMed ID: 24151445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus.
    Zenda S; Kojima T; Kato K; Izumi S; Ozawa T; Kiyota N; Katada C; Tsushima T; Ito Y; Akimoto T; Hasegawa Y; Kanamaru M; Daiko H
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):976-984. PubMed ID: 27745985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
    Minegaki T; Kuwahara A; Yamamori M; Nakamura T; Okuno T; Miki I; Omatsu H; Tamura T; Hirai M; Azuma T; Sakaeda T; Nishiguchi K
    Int J Med Sci; 2014; 11(4):321-6. PubMed ID: 24578608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
    Sakaeda T; Yamamori M; Kuwahara A; Hiroe S; Nakamura T; Okumura K; Okuno T; Miki I; Chayahara N; Okamura N; Tamura T
    Ther Drug Monit; 2008 Aug; 30(4):497-503. PubMed ID: 18641541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
    Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer.
    Kaneko K; Yano T; Minashi K; Kojima T; Ito M; Satake H; Yajima Y; Yoda Y; Ikematsu H; Oono Y; Hayashi R; Onozawa M; Ohtsu A
    Oncology; 2013; 84(1):57-64. PubMed ID: 23128894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
    Shiozaki A; Yamagishi H; Itoi H; Fujiwara H; Kikuchi S; Okamoto K; Ichikawa D; Fuji N; Ochiai T; Sonoyama T; Ueda Y
    Oncol Rep; 2005 Apr; 13(4):667-72. PubMed ID: 15756440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
    Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of CYFRA21-1, CEA and hemoglobin in patients with esophageal squamous cancer undergoing concurrent chemoradiotherapy.
    Zhang HQ; Wang RB; Yan HJ; Zhao W; Zhu KL; Jiang SM; Hu XG; Yu JM
    Asian Pac J Cancer Prev; 2012; 13(1):199-203. PubMed ID: 22502668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.
    Osawa S; Furuta T; Sugimoto K; Kosugi T; Terai T; Yamade M; Takayanagi Y; Nishino M; Hamaya Y; Kodaira C; Yamada T; Iwaizumi M; Takagaki K; Yoshida K; Kanaoka S; Ikuma M
    BMC Cancer; 2009 Nov; 9():408. PubMed ID: 19930599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.